These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31590967)

  • 41. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
    Schwartz L; Kip KE; Alderman E; Lu J; Bates ER; Srinivas V; Bach RG; Mighton LD; Feit F; King S; Frye RL;
    Am J Cardiol; 2009 Mar; 103(5):632-8. PubMed ID: 19231325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
    Rezende PC; Hueb W; Garzillo CL; Lima EG; Hueb AC; Ramires JA; Kalil Filho R
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1105-12. PubMed ID: 22944095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
    Holper EM; Addo T
    Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.
    Ismail-Beigi F; Lombardero MS; Escobedo J; Genuth S; Green J; Massaro E; Mooradian AD; Ovalle F; Whitehouse F; Zonszein J;
    J Diabetes Complications; 2014; 28(1):101-9. PubMed ID: 23478173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery: A Systematic Review and Meta-analysis.
    Munnee K; Bundhun PK; Quan H; Tang Z
    Medicine (Baltimore); 2016 Mar; 95(10):e3006. PubMed ID: 26962814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Magee MF; Isley WL;
    Am J Cardiol; 2006 Jun; 97(12A):20G-30G. PubMed ID: 16813735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
    Singh A; Schaff HV; Mori Brooks M; Hlatky MA; Wisniewski SR; Frye RL; Sako EY;
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):406-16. PubMed ID: 25968885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Five-Year Outcome After Off-Pump or On-Pump Coronary Artery Bypass Grafting in Elderly Patients.
    Diegeler A; Börgermann J; Kappert U; Hilker M; Doenst T; Böning A; Albert M; Färber G; Holzhey D; Conradi L; Rieß FC; Veeckmann P; Minorics C; Zacher M; Reents W
    Circulation; 2019 Apr; 139(16):1865-1871. PubMed ID: 30732456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contemporary Outcomes of Coronary Artery Bypass Grafting Among Patients With Insulin-Treated and Non-Insulin-Treated Diabetes.
    Li Z; Amsterdam EA; Young JN; Hoegh H; Armstrong EJ
    Ann Thorac Surg; 2015 Dec; 100(6):2262-9. PubMed ID: 26319487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease.
    Kuller LH
    Coron Artery Dis; 2010 Nov; 21(7):391-6. PubMed ID: 20634693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Brooks MM; Frye RL; Genuth S; Detre KM; Nesto R; Sobel BE; Kelsey SF; Orchard TJ;
    Am J Cardiol; 2006 Jun; 97(12A):9G-19G. PubMed ID: 16813734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term (10-Year) Outcomes of Stenting or Bypass Surgery for Left Main Coronary Artery Disease in Patients With and Without Diabetes Mellitus.
    Lee K; Ahn JM; Yoon YH; Kang DY; Park SY; Ko E; Park H; Cho SC; Park S; Kim TO; Lee PH; Lee SW; Park SW; Park DW; Park SJ
    J Am Heart Assoc; 2020 Apr; 9(8):e015372. PubMed ID: 32310027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Mäkikallio T; Holm NR; Lindsay M; Spence MS; Erglis A; Menown IB; Trovik T; Eskola M; Romppanen H; Kellerth T; Ravkilde J; Jensen LO; Kalinauskas G; Linder RB; Pentikainen M; Hervold A; Banning A; Zaman A; Cotton J; Eriksen E; Margus S; Sørensen HT; Nielsen PH; Niemelä M; Kervinen K; Lassen JF; Maeng M; Oldroyd K; Berg G; Walsh SJ; Hanratty CG; Kumsars I; Stradins P; Steigen TK; Fröbert O; Graham AN; Endresen PC; Corbascio M; Kajander O; Trivedi U; Hartikainen J; Anttila V; Hildick-Smith D; Thuesen L; Christiansen EH;
    Lancet; 2016 Dec; 388(10061):2743-2752. PubMed ID: 27810312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
    Ghasemzadeh N; Brooks MM; Vlachos H; Hardison R; Sikora S; Sperling L; Quyyumi AA; Epstein SE
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of diabetes on 12-month outcomes following coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry.
    Gitman MR; Okrainec K; Nguyen H; Duerr R; Del Core M; Fourchy D; Huynh T; Lader E; Rogers FJ; Chaudry MR; Pilote L; Eisenberg MJ;
    Can J Cardiol; 2005 Nov; 21(13):1169-74. PubMed ID: 16308592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status.
    BARI Investigators
    J Am Coll Cardiol; 2000 Apr; 35(5):1122-9. PubMed ID: 10758950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.
    Park DW; Ahn JM; Park H; Yun SC; Kang DY; Lee PH; Kim YH; Lim DS; Rha SW; Park GM; Gwon HC; Kim HS; Chae IH; Jang Y; Jeong MH; Tahk SJ; Seung KB; Park SJ;
    Circulation; 2020 May; 141(18):1437-1446. PubMed ID: 32223567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.